Thymosin Alpha-1: Evidence, Mechanism, Dosing & Legal Status

Thymosin alpha-1 (Talpha1; thymalfasin; brand Zadaxin) is a naturally occurring 28-amino-acid thymic peptide that acts as a calibrating immunomodulator. It is approved for hepatitis B, hepatitis C and as a cancer immunoadjuvant in more than thirty countries, but it is not approved by the FDA.1 Its popularity in wellness and longevity circles is large; its honest human evidence is real but indication-specific. This monograph separates the proven from the hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymosin alpha-1 is not FDA-approved in the United States. Dosing figures are reported strictly as seen in the published literature and approved foreign labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is thymosin alpha-1 and how does it work?

Thymosin alpha-1 is a 28-residue, N-acetylated acidic polypeptide (molecular weight about 3,108 Da), identical to the human peptide and produced for therapeutic use by chemical synthesis.1 It is generated in the body by proteolytic cleavage of the precursor prothymosin alpha; its low isoelectric point and acetylated N-terminus give partial protection against aminopeptidase degradation.1

Mechanistically the peptide is best understood as a bidirectional immune calibrator rather than a pure stimulant. Its principal innate-immune mechanism is Toll-like receptor signaling — chiefly TLR9 and TLR2 on dendritic cells and monocytes — engaging MyD88- and TRIF-dependent cascades, NF-kB and p38-MAPK, and driving production of IL-12, IFN-alpha and TNF-alpha.23 Downstream it promotes maturation of myeloid and plasmacytoid dendritic cells, enhances antigen presentation, drives CD4+ and CD8+ T-cell maturation with Th1 polarization, augments NK-cell cytotoxicity, and increases type I interferon output.3 A clinically important nuance is context dependence: the same peptide can restore exhausted T-cell compartments in immunosuppressed hosts yet help limit overactivation, which is why authors caution against labeling it purely stimulatory or suppressive.1112

The human pharmacokinetics are well characterized. After subcutaneous injection of 0.8 to 6.4 mg, the peptide is rapidly absorbed with a time-to-peak of about 2 hours and a serum half-life of about 2 hours, dose-proportional exposure, return to baseline by 24 hours, and no accumulation with repeated dosing; 31 to 60% is excreted in urine.1 Crucially, the biological effect outlasts the plasma half-life because the peptide induces durable shifts in immune-cell populations — the rationale for twice-weekly rather than daily dosing in chronic indications.1

What is the evidence by indication?

Thymosin alpha-1 has genuine human trials, but the strength varies sharply by indication. The table below summarizes the best available evidence for each.

The strongest human evidence is in chronic hepatitis B. A meta-analysis of 5 RCTs (353 participants) found thymosin alpha-1 monotherapy roughly threefold superior to placebo or usual care for virological response at 12 months post-treatment (OR 2.67, 95% CI 1.25 to 5.68), but no significant response at end of treatment or at 6 months — that is, a delayed effect.4 A 33-patient head-to-head RCT against interferon-alfa found no significant difference in complete response but markedly better tolerability for the peptide.5 Combination data are stronger still: pooled RCTs found the peptide plus lamivudine, and the peptide plus entecavir, superior to the antiviral alone.4 The caveat is that major hepatology guidelines do not currently include it in standard HBV regimens.4

The sepsis story is the most instructive. The early ETASS RCT showed a borderline 28-day mortality reduction (26.0% vs 35.0%; P=0.049) plus improved monocyte HLA-DR — promising but underpowered.7 The definitive phase 3 TESTS trial, registered as a 1,089-patient double-blind placebo-controlled study published in the BMJ in 2025, found no benefit: 28-day mortality 23.4% vs 24.1%, hazard ratio 0.99 (95% CI 0.77 to 1.27).6 Exploratory, Bonferroni-uncorrected subgroups hinted at heterogeneity by age and diabetes, but these are hypothesis-generating only.6 Older meta-analyses that predate or exclude TESTS favor the peptide, but they are dominated by smaller, lower-quality trials and are superseded by the negative phase 3 result.89

In cancer, the largest trial is a 488-patient randomized phase 2 in metastatic melanoma: tumor responses were numerically higher in the thymosin-containing arms than in the control arm, a positive immunologic signal without a definitive survival win.10 Retrospective propensity-matched data also associate the peptide with improved post-resection survival in HBV-related hepatocellular carcinoma.14 For COVID-19, the widely cited Wuhan study retrospectively reviewed 76 severe patients and associated the peptide with reduced mortality and reversal of T-cell exhaustion, with benefit greatest in the most lymphopenic patients; a separate 334-patient retrospective analysis found reduced 28-day mortality.1113 These are non-randomized and confounding-prone, and contemporaneous commentary urged caution; no positive RCT establishes a COVID-19 benefit.12

What doses appear in the literature?

Reported strictly as information, not a protocol. The approved hepatitis regimen on the Zadaxin label is 1.6 mg (about 900 ug/m2) subcutaneous twice weekly, injections roughly 3 to 4 days apart, for commonly 6 months in HBV, extendable to 12 months in partial responders; the pediatric or low-weight figure is 40 ug/kg.1 The product is a single-use vial of lyophilized peptide reconstituted with sterile water immediately before use, and the label specifies the subcutaneous route only — not for IV use.1 Sepsis trials used a more intensive short course: TESTS dosed every 12 hours for 7 days.67 Cancer trials used 1.6 to 6.4 mg subcutaneous in combination schedules, with the 3.2 mg arms carrying the strongest signal in the melanoma RCT.10 The pharmacokinetic rationale for twice-weekly chronic dosing is the roughly 2-hour half-life paired with durable downstream immune effects.1

How safe is thymosin alpha-1?

Across indications the peptide is described as well tolerated, with under 1% drug-related adverse events; reported effects are infrequent and mild — injection-site discomfort or erythema, rash, and rare reports of transient muscle atrophy and polyarthralgia with hand edema.1 In hepatitis B RCTs the only commonly reported issue was local injection-site discomfort, contrasting with the systemic toxicity of interferon, and the ETASS and TESTS sepsis RCTs recorded no serious drug-related adverse events.56 The contextual concerns are immunologic: because the peptide amplifies Th1, CD8 and dendritic-cell activity, the FDA's compounding evaluation flagged general peptide concerns around immunogenicity and uncharacterized immune effects for unapproved bulk material.16 The TESTS subgroup signal of possible higher mortality in younger sepsis patients is a reminder that immune modulation is context-dependent and not uniformly benign.6 Contraindications include known hypersensitivity, a relative contraindication in deliberate immunosuppression such as transplant recipients, and pregnancy Category C.1

What is the FDA and WADA status in 2026?

Thymosin alpha-1 is not FDA-approved for any indication in the United States, though it holds four orphan-drug designations, none of which has led to approval; it is approved abroad as Zadaxin or thymalfasin in more than thirty countries.116 The compounding timeline is precise: in September 2023 the FDA placed the peptide, with about 18 others including BPC-157 and TB-500, into 503A Category 2, effectively barring compounding-pharmacy use, prompting litigation against the agency.1517 On September 20, 2024 the FDA removed thymosin alpha-1 from Category 2 after the nominators withdrew their nominations, and referred it to the Pharmacy Compounding Advisory Committee.15 Net effect in 2026: the peptide is off Category 2 but not affirmatively listed or approved for compounding — a regulatory gray zone pending PCAC, with final determinations anticipated late 2026 to early 2027.16

For athletes the picture differs from its more notorious cousin. Thymosin alpha-1 is not explicitly named on the WADA Prohibited List, a key distinction from thymosin beta-4 (TB-500), which is explicitly prohibited at all times under category S2.3 — the two should never be conflated.18 That said, athletes should weigh the broad S2 language covering other growth factors and modulators, and the list governs only substances under WADA-signatory testing; the peptide has not been studied for athletic performance in any case.19

Bottom line. Thymosin alpha-1 is a real, approved drug abroad with a clean tolerability record and genuine human evidence — but that evidence is indication-specific. From a root-cause, immune-restoration lens it is most plausible specifically in measurably immunocompromised or lymphopenic states, not as a casual immune booster. The honest grade is B, not A, outside hepatitis B, and not a license for self-administration of unapproved material. Regulatory facts here are current as of June 2026 and should be re-verified after the next PCAC review.